Page 13 - மருந்துப்போலி கட்டுப்படுத்தப்படுகிறது படிப்பு நடத்தப்பட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துப்போலி கட்டுப்படுத்தப்படுகிறது படிப்பு நடத்தப்பட்டது. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துப்போலி கட்டுப்படுத்தப்படுகிறது படிப்பு நடத்தப்பட்டது Today - Breaking & Trending Today

Study: Antibiotics are not necessary after most endoscopic sinus surgeries


Study: Antibiotics are not necessary after most endoscopic sinus surgeries
Antibiotics are not necessary for patients after most routine endoscopic sinus surgeries despite the common practice to prescribe them, according to a team led by researchers at Massachusetts Eye and Ear.
In a new randomized controlled trial, patients who underwent endoscopic sinus surgery had no differences in outcomes including symptoms and infections whether they took an antibiotic or placebo after surgery.
The only reported difference in outcomes was in side effects, with patients in the antibiotic group 10 times more likely to report symptoms like diarrhea.
The trial s findings were published December 19 in ....

United States , Erich Holbrook , Staceyt Gray , Emily Henderson , Neck Surgery At Harvard Medical School , Study Co , Division Of Rhinology , International Forum Of Allergy Rhinology , Sinus Center At Mass Eye , Harvard Medical School , Massachusetts Eye , International Forum , Study Co Senior Author , Mass Eye , Associate Professor , Neck Surgery , Harvard Medical , Sinus Center , Health Care , Medical School , ஒன்றுபட்டது மாநிலங்களில் , எரிச் ஹோல்ப்ரூக் , எமிலி ஹென்டர்சன் , கழுத்து அறுவை சிகிச்சை இல் ஹார்வர்ட் மருத்துவ பள்ளி , படிப்பு இணை , நீர் சேர்க்கை மையம் இல் நிறை கண் ,

UC-MSC infusions reduce risk of death, quicken recovery time in severe COVID-19 cases


UC-MSC infusions reduce risk of death, quicken recovery time in severe COVID-19 cases
Dr. Camilo Ricordi, director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, and his team of international collaborators are reporting the results of a groundbreaking randomized controlled trial showing umbilical cord-derived mesenchymal stem cell (UC-MSC) infusions safely reduce risk of death and quicken time to recovery for the most severe COVID-19 patients. Dr. Ricordi s peer-reviewed paper has just been published in
STEM CELLS Translational Medicine (SCTM) January 2021.
The clinical trial, authorized by the FDA last April, was initiated by The Cure Alliance, a 501(c)(3) non-profit organization of research scientists founded ten years ago by Dr. Ricordi for scientists around the world to share knowledge and accelerate cures of all diseases. ....

United States , Miller School , University Of Miami , Arnoldi Caplan , Camilo Ricordi , Fondazione Silvio Tronchetti Provera , Giacomo Lanzoni , Emily Henderson , Shelley Ross , Diabetes Research Institute , Lanzoni Is Research Assistant Professor , National Center , University Of Miami Health System , Cure Alliance , Jackson Health System , Barilla Group , Department Of Biochemistry , Cell Transplant Center , Translational Sciences , University Of Miami Miller School Medicine , Diabetes Research Institute Foundation , Simkins Family Foundation , Case Western Reserve University , Miami Miller School , Miami Tower , Jackson Memorial Hospital ,

Pfizer and BioNTech to offer COVID vaccine to volunteers who got placebo

The trial's Vaccine Transition Option allows all participants aged 16 or older the choice to discover whether they were given the placebo, "and for participants who learn they received the placebo, to have the option to receive the investigational vaccine while staying in the study," the companies said on their website https://www.covidvaccinestudy.com/participants for trial participants. The U.S. Food and Drug Administration and a panel of its outside advisers have expressed concerns over Pfizer's "unblinding" plan, saying it could make it harder to continue collecting data on safety and effectiveness needed to win full FDA approval of the vaccine. Trial participants who received the placebo will have two doses of the investigational vaccine reserved for them within the study, the companies said on the website. ....

Aakriti Bhalla , Daniel Wallis , Us Centers For Disease , Pfizer Inc , Drug Administration , Vaccine Transition Option , Disease Control , Investigational Vaccine , Trial Participants , Vaccine Trial , ஆக்ரீதி பல்லா , டேனியல் வாலிஸ் , எங்களுக்கு மையங்கள் க்கு நோய் , ஃபைசர் இன்க் , தடுப்பூசி மாற்றம் விருப்பம் , நோய் கட்டுப்பாடு , தடுப்பூசி சோதனை ,